Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension

Veronika Vakhapova, Yael Richter, Tzafra Cohen, Yael Herzog, Amos D Korczyn, Veronika Vakhapova, Yael Richter, Tzafra Cohen, Yael Herzog, Amos D Korczyn

Abstract

Background: Phosphatidylserine (PS) is a naturally occurring phospholipid present in the inner leaflet of mammalian plasma membranes. Administration of PS extracted from bovine cortex (BC-PS), which contains high levels of omega-3 long chain polyunsaturated fatty acid (LC-PUFA) attached to its backbone, resulted in positive effects on brain functions such as learning and memory. Recently, a novel marine-sourced PS with omega-3 LC-PUFA attached to its backbone was developed (PS-DHA). In the present study, we evaluated the safety profile of the novel PS preparation in non-demented elderly with memory complaints. The efficacy study of this novel formulation indicated that PS-DHA may ameliorate cognitive deficits in non-demented elderly population.

Methods: 157 non-demented elderly participants with memory complaints were randomized to receive either PS-DHA (300 mg PS/day) or placebo for 15 weeks. Standard biochemical and hematological safety parameters, blood pressure and heart rate were evaluated at baseline and endpoint. 122 participants continued into an open-label extension for additional 15 weeks, in which they all consumed PS-DHA (100 mg PS/day) and were evaluated for their blood pressure, heart rate and weight at endpoint. Adverse events were monitored throughout the double-blind and open-label phases.

Results: 131 participants completed the double-blind phase. No significant differences were found in any of the tested safety parameters between the study groups, or within each group. 121 participants completed the open-label phase. At the end of this phase, there was a reduction in resting diastolic blood pressure and a slight weight gain among participants who consumed PS-DHA for 30 weeks.

Conclusions: The results of this study indicate that consumption of PS-DHA at a dosage of 300 mg PS/day for 15 weeks, or 100 mg PS/day for 30 weeks, is safe, well tolerated, and does not produce any negative effects in the tested parameters.

Trial registration: clinicaltrials. gov, identifier: NCT00437983.

References

    1. Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res. 2005;44(4):207–234. doi: 10.1016/j.plipres.2005.05.001.
    1. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41(5):644–649.
    1. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993;5(2):123–133.
    1. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull. 1988;24(1):130–134.
    1. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28(1):61–66.
    1. Palmieri G, Palmieri R, Inzoli MR, Lombardi G, Sottini C, Tavolato B, Giometto B. Double blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clinical Trials Journal. 1987;24(1):73–83.
    1. Puca FM, Bavarese MA, Minervini MG. Exploratory trial of PS efficacy in mildly demented patients. Cinical Trials Journal. 1987;24:94–98.
    1. Rabboni M, Maggioni FS, Giannelli A, Beinat L. Neuroendocrine and behavioral effects of PS in elderly patients with abiotrophic or vascular dementia or mild depression. Clinical Trials Journal. 1990;27:230–240.
    1. Jager R, Purpura M, Kingsley M. Phospholipids and sports performance. J Int Soc Sports Nutr. 2007;4:5. doi: 10.1186/1550-2783-4-5.
    1. Benton D, Donohoe RT, Sillance B, Nabb S. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci. 2001;4(3):169–178.
    1. Hellhammer J, Fries E, Buss C, Engert V, Tuch A, Rutenberg D, Hellhammer D. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress. 2004;7(2):119–126. doi: 10.1080/10253890410001728379.
    1. Jorissen BL, Brouns F, Van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci. 2001;4(2):121–134.
    1. Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, Lerer B. An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci. 2000;37(4):302–307.
    1. Jorissen BL, Brouns F, Van Boxtel MP, Riedel WJ. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci. 2002;5(5):337–343. doi: 10.1080/1028415021000033802.
    1. Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, Bodennec J. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr. 2008;87(5):1170–1180.
    1. Vaisman N, Pelled D. n-3 phosphatidylserine attenuated scopolamine-induced amnesia in middle-aged rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):952–959. doi: 10.1016/j.pnpbp.2009.04.021.
    1. Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. Phosphatidylserine Containing omega-3 Fatty Acids May Improve Memory Abilities in Non-Demented Elderly with Memory Complaints: A Double-Blind Placebo-Controlled Trial. Dement Geriatr Cogn Disord. pp. 467–474.
    1. Crook TH, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr. 1992;4(2):165–176. doi: 10.1017/S1041610292000991.
    1. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62(2):275–280.
    1. Albanese E, Dangour AD, Uauy R, Acosta D, Guerra M, Guerra SSG, Huang Y, Jacob KS, Llibre de Rodriguez J, Noriega LH. et al.Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based study. Am J Clin Nutr. 2009;90(2):392–400. doi: 10.3945/ajcn.2009.27580.
    1. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. 2005;65(9):1409–1414. doi: 10.1212/01.wnl.0000183148.34197.2e.
    1. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Investigation. 2005;35:691–699. doi: 10.1111/j.1365-2362.2005.01570.x.
    1. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, Tamura Y, Yazawa K, Hirayama T. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids. 1999;34(Suppl):S345–346.
    1. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6):456–464. doi: 10.1016/j.jalz.2010.01.013.
    1. Wheeler KP, Whittam R. ATPase activity of the sodium pump needs phosphatidylserine. Nature. 1970;225(5231):449–450. doi: 10.1038/225449a0.
    1. Bittova L, Stahelin RV, Cho W. Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity. J Biol Chem. 2001;276(6):4218–4226. doi: 10.1074/jbc.M008491200.
    1. Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res. 2008;49(7):1377–1387. doi: 10.1194/jlr.R700020-JLR200.
    1. Pepeu G, Pepeu IM, Amaducci L. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res. 1996;33(2):73–80. doi: 10.1006/phrs.1996.0013.
    1. Pepping J. Phosphatidylserine. American Journal of Health-System Pharmacy. 1999;56:2043–2044.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅